Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
101.78 (1y: +35%)
Market Cap 19.52 B P/E(ttm) 13.50
Enterprise Value 21.27 B P/B
BDX- NYSE (USA)
Becton Dickinson & Co
  • Currently 3.5/5
Business Predictability Rank: 3.5-Star (On Watch)
Back Testing Results:
Average gain of all 3.5-Star stocks: 9.3% per year.
% of Stocks that are in still loss if held for 10yrs: 9%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$101.78
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt No Debt
BDX's Cash to Debt is ranked lower than
73% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.43 vs. BDX: No Debt )
BDX' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: No Debt
Interest Coverage 16.5
BDX's Interest Coverage is ranked lower than
57% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 46.10 vs. BDX: 16.5 )
BDX' s 10-Year Interest Coverage Range
Min: 8   Max: No Debt
Current: 16.5
F-Score: 5
Z-Score: 4.45
M-Score: -2.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 20.70
BDX's Operating margin (%) is ranked higher than
81% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. BDX: 20.70 )
BDX' s 10-Year Operating margin (%) Range
Min: 15.8   Max: 23
Current: 20.7
15.8
23
Net-margin (%) 19.7
BDX's Net-margin (%) is ranked higher than
81% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.30 vs. BDX: 19.7 )
BDX' s 10-Year Net-margin (%) Range
Min: 9.5   Max: 19.7
Current: 19.7
9.5
19.7
Revenue Growth (%) 5.5
BDX's Revenue Growth (%) is ranked higher than
73% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.40 vs. BDX: 5.5 )
BDX' s 10-Year Revenue Growth (%) Range
Min: 4.3   Max: 9
Current: 5.5
4.3
9
EBITDA Growth (%) 3.4
BDX's EBITDA Growth (%) is ranked higher than
73% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. BDX: 3.4 )
BDX' s 10-Year EBITDA Growth (%) Range
Min: 3.4   Max: 11.2
Current: 3.4
3.4
11.2
EPS Growth (%) 8.1
BDX's EPS Growth (%) is ranked higher than
75% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.15 vs. BDX: 8.1 )
BDX' s 10-Year EPS Growth (%) Range
Min: 2.9   Max: 18.5
Current: 8.1
2.9
18.5
» BDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

BDX Guru Trades in Q2 2012

Richard Pzena 1,573,102 sh (+1055.42%)
Ray Dalio 56,174 sh (+445.38%)
Jeff Auxier 44,950 sh (+221.07%)
Steven Cohen 10,347 sh (+105.71%)
Joel Greenblatt 5,870 sh (+102.55%)
Mario Gabelli 685,385 sh (+10.06%)
Donald Yacktman 2,114,360 sh (+1.02%)
Vanguard Health Care Fund 3,102,500 sh (unchged)
Bill Frels 5,239 sh (unchged)
Robert Olstein 92,000 sh (unchged)
Michael Price 242,500 sh (unchged)
Richard Perry Sold Out
Dodge & Cox 23,280 sh (-0.51%)
Ruane Cunniff 1,103,287 sh (-3.74%)
Jeremy Grantham 330,710 sh (-4.37%)
Manning & Napier Advisors, Inc 3,354,375 sh (-12.08%)
John Hussman 250,750 sh (-16.63%)
Pioneer Investments 2,067,801 sh (-23.52%)
Mark Hillman 2,912 sh (-55.89%)
Jim Simons 108,700 sh (-74.19%)
Paul Tudor Jones 5,200 sh (-98.12%)
Chris Davis 5,586 sh (-99.69%)
» More
Q3 2012

BDX Guru Trades in Q3 2012

Joel Greenblatt 31,092 sh (+429.68%)
Richard Pzena 3,121,741 sh (+98.44%)
Mario Gabelli 691,455 sh (+0.89%)
Donald Yacktman 2,119,982 sh (+0.27%)
Yacktman Focused Fund 770,000 sh (unchged)
Michael Price 242,500 sh (unchged)
Yacktman Fund 800,000 sh (unchged)
Vanguard Health Care Fund 3,102,500 sh (unchged)
Robert Olstein 92,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Mark Hillman 2,871 sh (-1.41%)
Jeff Auxier 44,000 sh (-2.11%)
Dodge & Cox 22,780 sh (-2.15%)
Jeremy Grantham 322,710 sh (-2.42%)
Manning & Napier Advisors, Inc 3,252,006 sh (-3.05%)
Bill Frels 5,050 sh (-3.61%)
Chris Davis 4,603 sh (-17.6%)
Pioneer Investments 1,249,312 sh (-39.58%)
Ray Dalio 26,478 sh (-52.86%)
Ruane Cunniff 5,725 sh (-99.48%)
John Hussman 750 sh (-99.7%)
» More
Q4 2012

BDX Guru Trades in Q4 2012

Jim Simons 114,400 sh (New)
Steven Cohen 841 sh (New)
John Hussman 1,125 sh (+50%)
Ray Dalio 35,278 sh (+33.24%)
Richard Pzena 3,332,209 sh (+6.74%)
Bill Frels 5,375 sh (+6.44%)
Donald Yacktman 2,131,060 sh (+0.52%)
Jeff Auxier 44,150 sh (+0.34%)
Yacktman Fund 800,000 sh (unchged)
Robert Olstein 92,000 sh (unchged)
Yacktman Focused Fund 770,000 sh (unchged)
Michael Price 242,500 sh (unchged)
Jeremy Grantham 492,083 sh (unchged)
Chris Davis 4,600 sh (-0.07%)
Mark Hillman 2,863 sh (-0.28%)
Mario Gabelli 680,305 sh (-1.61%)
Manning & Napier Advisors, Inc 3,066,379 sh (-5.71%)
Vanguard Health Care Fund 2,902,500 sh (-6.45%)
Dodge & Cox 20,680 sh (-9.22%)
Pioneer Investments 1,082,536 sh (-13.35%)
Ruane Cunniff 4,099 sh (-28.4%)
Joel Greenblatt 15,334 sh (-50.68%)
» More
Q1 2013

BDX Guru Trades in Q1 2013

Paul Tudor Jones 6,600 sh (New)
Ken Fisher 2,461 sh (New)
John Hussman 202,325 sh (+17884.4%)
Jeremy Grantham 897,983 sh (+82.49%)
Joel Greenblatt 22,510 sh (+46.8%)
Richard Pzena 3,474,918 sh (+4.28%)
Yacktman Focused Fund 770,000 sh (unchged)
Michael Price 242,500 sh (unchged)
Chris Davis 4,600 sh (unchged)
Yacktman Fund 800,000 sh (unchged)
Ray Dalio Sold Out
Mark Hillman Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
Jeff Auxier 44,100 sh (-0.11%)
Pioneer Investments 1,075,038 sh (-0.69%)
Dodge & Cox 20,480 sh (-0.97%)
Donald Yacktman 2,108,865 sh (-1.04%)
Mario Gabelli 658,795 sh (-3.16%)
Bill Frels 5,175 sh (-3.72%)
Vanguard Health Care Fund 2,757,500 sh (-5%)
Manning & Napier Advisors, Inc 2,838,034 sh (-7.45%)
Robert Olstein 81,000 sh (-11.96%)
Ruane Cunniff 2,272 sh (-44.57%)
» More
» Details

Insider Trades

Latest Guru Trades with BDX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Add 17884.4%0.71%$78.19 - $95.61 $ 101.7817%202325
Mark Hillman 2013-03-31 Sold Out 0.66%$78.19 - $95.61 $ 101.7817%0
Joel Greenblatt 2013-03-31 Add 46.8%0.04%$78.19 - $95.61 $ 101.7817%22510
Ray Dalio 2013-03-31 Sold Out 0.03%$78.19 - $95.61 $ 101.7817%0
Ruane Cunniff 2013-03-31 Reduce -44.57%$78.19 - $95.61 $ 101.7817%2272
Ken Fisher 2013-03-31 New Buy$78.19 - $95.61 $ 101.7817%2461
Richard Pzena 2012-12-31 Add 6.74%0.13%$74.63 - $79.46 $ 101.7832%3332209
Joel Greenblatt 2012-12-31 Reduce -50.68%0.08%$74.63 - $79.46 $ 101.7832%15334
Ray Dalio 2012-12-31 Add 33.24%0.01%$74.63 - $79.46 $ 101.7832%35278
Ruane Cunniff 2012-12-31 Reduce -28.4%$74.63 - $79.46 $ 101.7832%4099
John Hussman 2012-12-31 Add 50%$74.63 - $79.46 $ 101.7832%1125
Richard Pzena 2012-09-30 Add 98.44%0.99%$73.16 - $79.49 $ 101.7834%3121741
Ruane Cunniff 2012-09-30 Reduce -99.48%0.67%$73.16 - $79.49 $ 101.7834%5725
John Hussman 2012-09-30 Reduce -99.7%0.35%$73.16 - $79.49 $ 101.7834%750
Joel Greenblatt 2012-09-30 Add 429.68%0.13%$73.16 - $79.49 $ 101.7834%31092
Ray Dalio 2012-09-30 Reduce -52.86%0.03%$73.16 - $79.49 $ 101.7834%26478
Richard Pzena 2012-06-30 Add 1055.42%1.28%$71.79 - $77.96 $ 101.7835%1573102
Chris Davis 2012-06-30 Reduce -99.69%0.3%$71.79 - $77.96 $ 101.7835%5586
Mark Hillman 2012-06-30 Reduce -55.89%0.25%$71.79 - $77.96 $ 101.7835%2912
Ray Dalio 2012-06-30 Add 445.38%0.05%$71.79 - $77.96 $ 101.7835%56174
Richard Perry 2012-06-30 Sold Out 0.04%$71.79 - $77.96 $ 101.7835%0
Joel Greenblatt 2012-06-30 Add 102.55%0.02%$71.79 - $77.96 $ 101.7835%5870
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 13.50
BDX's P/E(ttm) is ranked higher than
86% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.40 vs. BDX: 13.50 )
BDX' s 10-Year P/E(ttm) Range
Min: 10.27   Max: 30.76
Current: 13.5
10.27
30.76
P/S 2.61
BDX's P/S is ranked lower than
51% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. BDX: 2.61 )
BDX' s 10-Year P/S Range
Min: 1.7   Max: 3.54
Current: 2.61
1.7
3.54
PFCF 21.12
BDX's PFCF is ranked higher than
79% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.35 vs. BDX: 21.12 )
BDX' s 10-Year PFCF Range
Min: 12.85   Max: 1600
Current: 21.12
12.85
1600
EV-to-EBIT 13.2
BDX's EV-to-EBIT is ranked higher than
79% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.12 vs. BDX: 13.2 )
BDX' s 10-Year EV-to-EBIT Range
Min: 9.2   Max: 21.2
Current: 13.2
9.2
21.2
PEG 2.87
BDX's PEG is ranked higher than
88% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. BDX: 2.87 )
BDX' s 10-Year PEG Range
Min: 0.9   Max: 3.81
Current: 2.87
0.9
3.81
Shiller P/E 17.63
BDX's Shiller P/E is ranked higher than
81% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.85 vs. BDX: 17.63 )
BDX' s 10-Year Shiller P/E Range
Min: 13.79   Max: 33.69
Current: 17.63
13.79
33.69

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 1.86
BDX's Dividend Yield is ranked higher than
88% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. BDX: 1.86 )
BDX' s 10-Year Dividend Yield Range
Min: 0.92   Max: 2.44
Current: 1.86
0.92
2.44
Dividend growth (3y) 5.7
BDX's Dividend growth (3y) is ranked higher than
95% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. BDX: 5.7 )
BDX' s 10-Year Dividend growth (3y) Range
Min: 2   Max: 21.1
Current: 5.7
2
21.1
Yield on cost (5-Year) 3.35
BDX's Yield on cost (5-Year) is ranked higher than
96% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. BDX: 3.35 )
BDX' s 10-Year Yield on cost (5-Year) Range
Min: 1.62   Max: 4.3
Current: 3.35
1.62
4.3
Share Buyback Rate 3.9
BDX's Share Buyback Rate is ranked higher than
98% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -1.70 vs. BDX: 3.9 )
BDX' s 10-Year Share Buyback Rate Range
Min: 4   Max: -0.1
Current: 3.9

Valuation & Return

vs
industry		 vs
history
Earnings Yield (Greenblatt) 7.60
BDX's Earnings Yield (Greenblatt) is ranked higher than
85% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BDX: 7.60 )
BDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.7   Max: 10.8
Current: 7.6
4.7
10.8
Forward Rate of Return (Yacktman) 9.27
BDX's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.11 vs. BDX: 9.27 )
BDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.2   Max: 20
Current: 9.27
9.2
20

Business Description

Becton Dickinson & Co., was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897. The Company is a global medical technology Company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Its operations consist of three worldwide business segments: BD Medical, BD Diagnostics and BD Biosciences. BD Medical produces an array of medical devices that are used in a range of healthcare settings. They include many safety-engineered injection, infusion and surgery products. BD Medical's product lines include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes; prefillable drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; surgical blades/scalpels and regional anesthesia needles and trays; critical care monitoring devices; ophthalmic surgical instruments; and sharps disposal containers. BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instrument systems and reagents to detect a range of infectious diseases, healthcare-associated infections (HAIs) and cancers. BD Diagnostics' products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and HAIs; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; and plated media. BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. BD Biosciences' product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The main customers served by BD Biosciences are research and clinical laboratories; academic and government institutions; pharmaceutical and biotechnology companies; hospitals; and blood banks. The main products sold by BD outside of the U.S. are needles and syringes; insulin syringes and pen needles; diagnostic systems; BD Vacutainer (tm) brand blood collection products; BD Hypak(tm) brand prefillable syringe systems; infusion therapy products; flow cytometry instruments and reagents; and disposable laboratory products. BD has manufac
Company Website
SEC Reports
Industry: Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO
Traded in other countries:BOX.Germany
» More Articles for BDX

Headlines

Articles On GuruFocus.com
Medtronic Inc. (MDT) Dividend Stock Analysis Mar 29 2013 
The Best Yielding Ex-Dividend Stocks On March 06, 2013 Mar 05 2013 
Becton Dickinson 2013 Dividend Stock Analysis Feb 19 2013 
Early Movers for Tuesday February 5, 2013 Feb 05 2013 
Motiwala Capital - Q4 2012 Letter to Investors Feb 01 2013 
Evaluating Dividend Growth Stocks – The Missing Ingredient Jan 29 2013 
Becton Dickinson (BDX) Dividend Stock Analysis Jan 04 2013 
Why I am not worried about the Fiscal Cliff and Dividend Tax Increases Dec 17 2012 
Donald Yacktman Finds Two Undervalued Companies in His Most Bought, In-Favor Sector of Q3 Dec 04 2012 
The Other Healthcare Stocks of Warren Buffett Dec 05 2012 

More From Our Partners
5 Healthcare Stocks With The Highest EPS May 14 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial